Warning: The NCBI web site requires JavaScript to function. more...
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
Breast Cancer Res. 2009;11(3):R27. Epub 2009 May 11.
Related citations
Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.
Histopathology. 2009 Sep;55(3):346-52.
Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.
J Surg Res. 2007 Nov;143(1):109-18.
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6. Epub 2008 Aug 28.
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.
Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.
Ann Oncol. 2005 Nov;16(11):1755-61. Epub 2005 Aug 5.
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
J Clin Pathol. 2005 Jun;58(6):611-6.
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
Cancer. 2008 Mar 1;112(5):995-1000.
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.
Breast Cancer Res. 2008;10(3):R46. Epub 2008 May 16.
Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.
Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M.
Pathol Oncol Res. 2006;12(2):83-6. Epub 2006 Jun 24.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.
J Natl Cancer Inst. 2009 May 20;101(10):736-50. Epub 2009 May 12.
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, Henshall SM, Visvader JE, Sutherland RL.
Int J Cancer. 2010 Mar 15;126(6):1445-53.
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Christiaens MR, Vergote I.
Breast Cancer Res Treat. 2005 May;91(1):81-7.
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.
Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Wael T, Eiman G.
Indian J Cancer. 2006 Oct-Dec;43(4):163-8.
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.
Breast Cancer Res Treat. 2011 Jul;128(2):315-26. Epub 2010 Aug 10.
MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer.
Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN.
Cell Cycle. 2011 Feb 1;10(3):507-17. Epub 2011 Feb 1.
Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J, Filas V, Buszkiewicz E, Trzeciak P, Wojciechowski M, Koktysz R, Staniszewski W, Breborowicz J, Rojo MG.
Folia Histochem Cytobiol. 2010 Jan 1;48(1):19-25.
Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG, Malmgren JA.
Breast J. 2008 Sep-Oct;14(5):456-63. Epub 2008 Jul 24.
Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M, Bauer K, Pare M.
Breast Cancer Res Treat. 2010 Feb;120(1):217-27. Epub 2009 Jul 21.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on